Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

NCT06498622 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Donafenib + Envafolimab

Sponsor

Anhui Provincial Hospital